What the FDA labels say about taking them together
Amiodarone and moxifloxacin
Moxifloxacin's FDA label of March 17, 2026 names amiodarone in its warnings and precautions section; amiodarone's label does not name moxifloxacin itself but warns about its class (Fluoroquinolones). The moxifloxacin label: “The drug should be avoided in patients with known prolongation of the QT interval, patients with uncorrected hypokalemia and patients receiving Class IA or Class III antiarrhythmic agents, due to the lack of clinical …”
Check it at the source: the amiodarone FDA label on DailyMed (effective December 9, 2025, Chartwell RX, LLC); the moxifloxacin FDA label on DailyMed (effective March 17, 2026, Macleods Pharmaceuticals Limited).
What does the amiodarone label say about moxifloxacin?
Amiodarone's label does not name moxifloxacin itself; it warns about its class (Fluoroquinolones):
Amiodarone label, drug interactionsAmiodarone Drug Interactions Concomitant Drug Class/Name Examples Clinical Comment Pharmacodynamic Interactions QT Prolonging Drugs class I and III antiarrhythmics, lithium, certain phenothiazines, tricyclic antidepressants, certain fluoroquinolone and macrolide antibiotics, azole antifungals, halogenated inhalation anesthetic agents Increased risk of Torsade de Pointes.
Amiodarone label, drug interactionsPharmacokinetic Interactions CYP450 Inhibitors grapefruit juice, certain fluoroquinolone and macrolide antibiotics, azole antifungals, cimetidine, certain protease inhibitors Increased exposure of amiodarone.
Source: FDA drug label (Amiodarone Hydrochloride), Chartwell RX, LLC, effective December 9, 2025 (SPL set 5520f11d-968d-4f4f-bf57-d14369c0d746), via openFDA; the full label on DailyMed
What does the moxifloxacin label say about amiodarone?
Moxifloxacin label, warnings and precautionsKnown prolongation of the QT interval Ventricular arrhythmias including torsade de pointes because QT prolongation may lead to an increased risk for these conditions Ongoing proarrhythmic conditions, such as clinically significant bradycardia and acute myocardial ischemia, Uncorrected hypokalemia or hypomagnesemia Class IA (for example, quinidine, procainamide) or Class III (for example, amiodarone, sotalol) antiarrhythmic agents Other drugs that prolong the QT interval such as cisapride, erythromycin, antipsychotics, and tricyclic antidepressants Elderly patients using intravenous moxifloxacin may be more susceptible to drug-associated QT prolongation [see Use In Specific Populations ( 8.5 …
Moxifloxacin label (Fresenius Kabi USA, LLC, May 6, 2024), warnings and precautionsThe drug should be avoided in patients with known prolongation of the QT interval, patients with uncorrected hypokalemia and patients receiving Class IA (for example, quinidine, procainamide) or Class III (for example, amiodarone, sotalol) antiarrhythmic agents, due to the lack of clinical experience with the drug in these patient populations.
Source: FDA drug label (Moxifloxacin, NDA205572), Fresenius Kabi USA, LLC, effective May 6, 2024 (SPL set a4e28b09-714b-46e7-b4e6-0163cad78fc5), via openFDA
Source: FDA drug label (Moxifloxacin), Macleods Pharmaceuticals Limited, effective March 17, 2026 (SPL set 182ecd0f-714f-42f0-9b16-fb604cf15786), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Amiodarone | Moxifloxacin | |
|---|---|---|
| Labeled for | n/a | Bacterial infections |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.122 per tablet 200 mg tablet | $1.60 per mL 0.5% eye drops |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once